3rd Cir. Reinstates Failure-To-Warn Claims in Fosamax MDL, Says Preemption Issue is Fact Dependent



DOCUMENTS
  • Opinion


PHILADELPHIA — A federal appeals court has reinstated failure-to-warn claims asserted against Merck in the federal Fosamax femur fracture multidistrict litigation, ruling that the issue of preemption is a question of fact for the jury and cannot be decided at the summary judgment stage.

In a March 22 opinion, the 3rd Circuit U.S. Court of Appeals explained that under the “clear evidence” standard set forth in Wyeth v. Levine, the factfinder must conclude that it is highly probable that the FDA would not have approved a label change. The term refers solely to the applicable standard of proof, and therefore …

FIRM NAMES
  • Carella Byrne Cecchi Olstein Brody & Agnello
  • Fox Rothschild
  • Hughes Hubbard & Reed
  • Kellogg Hansen Todd Figel & Frederick
  • King & Spalding
  • Skadden Arps Slate Meagher & Flom
  • Venable
  • Weitz & Luxenberg





UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS